52050-17-6
Chemical Structure
Glucosylsphingosine
Synonym(s): Glucopsychosine; Lyso-Gb1; Lyso-GL1
- CAS No.: 52050-17-6
- Formula:C24H47NO7
- Molecular Weight:461.63
IUPAC Name: (2R,3R,4S,5S,6R)-2-(((2S,3R,E)-2-amino-3-hydroxyoctadec-4-en-1-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
InChIKey: HHJTWTPUPVQKNA-JIAPQYILSA-N
SMILES: O[C@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)[C@@H]1OC[C@H](N)[C@H](O)/C=C/CCCCCCCCCCCCC
Biological Activity: Glucosylsphingosine (lyso-Gb1) is a deacylated form of glucosylceramide with neurotoxicity and is also a noncompetitively inhibitor of glucocerebrosidase with a Ki value of 30 μM. Glucosylsphingosine is promising for research of Krabbe and Gaucher disease[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Glucosylsphingosine | 99.68% | Glucosylsphingosine (lyso-Gb1) is a deacylated form of glucosylceramide with neurotoxicity and is also a noncompetitively inhibitor of glucocerebrosidase with a Ki value of 30 μM. Glucosylsphingosine is promising for research of Krabbe and Gaucher disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glucosylsphingosine-13C6 | 98% | Glucosylsphingosine-13C6 (Glucopsychosine-13C6) is the 13C-labeled Glucosylsphingosine (HY-N7745). Glucosylsphingosine (lyso-Gb1) is a deacylated form of glucosylceramide with neurotoxicity and is also a noncompetitively inhibitor of glucocerebrosidase with a Ki value of 30 μM. Glucosylsphingosine is promising for research of Krabbe and Gaucher disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glucosylsphingosine-d5 | 99.0% | Glucosylsphingosine-d5 is the deuterium labeled Glucosylsphingosine. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glucosylsphingosine-d7 | 99.04% | Glucosylsphingosine-d7 is deuterium labeled Glucosylsphingosine. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hurvitz N, et al. Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease. Int J Mol Sci. 2019 Jun 21;20(12):3033. [Content Brief]
- [2]. Dekker N, et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood. 2011 Oct 20;118(16):e118-27. [Content Brief]
- [3]. Schueler UH, et al. Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3. Neurobiol Dis. 2003 Dec;14(3):595-601. [Content Brief]
- [4]. Stahl-Meyer K, et al. Galactosyl- and glucosylsphingosine induce lysosomal membrane permeabilization and cell death in cancer cells. PLoS One. 2022 Nov 21;17(11):e0277058. [Content Brief]
- [5]. Atsumi S, et al. Accumulation of tissue glucosylsphingosine in Gaucher-like mouse induced by the glucosylceramidase inhibitor cyclophellitol. Arch Biochem Biophys. 1993 Jul;304(1):302-4. [Content Brief]
- [6]. Lukas J, et al. Glucosylsphingosine Causes Hematological and Visceral Changes in Mice-Evidence for a Pathophysiological Role in Gaucher Disease. Int J Mol Sci. 2017 Oct 20;18(10):2192. [Content Brief]
